Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs Sana Biotechnology Inc — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $26.09 (market cap $159.33M), while Sana Biotechnology Inc trades at $2.82 (market cap $836.71M). The key difference: Sana Biotechnology Inc is far larger — about 5.3× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Roundhill Russell 2000 0DTE Covered Call Strat ETF is more actively traded (248,058 versus 4,507,444). Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 53 Days and Sana Biotechnology Inc for 23 Days on average.
| RDTE | SANA | |
|---|---|---|
Market Cap | $159.33M | $836.71M |
Volume | 248,058 | 4,507,444 |
Sector | Income / Options Overlay | Health |
52-Week High | $33.66 | $5.92 |
52-Week Low | $25.96 | $2.68 |
Typical Hold Time | 53 Days | 23 Days |
Enterprise Value | — | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
